Table 1.
Tumour samples are listed along with their pathogenic variant detected either by diagnostic test or by whole genome sequencing where known (column 2)
| (ALL) N = 52 | N | |
|---|---|---|
| Group | 52 | |
| HRAS | 2 (3.85%) | |
| IDH3B | 1 (1.92%) | |
| NF1 | 1 (1.92%) | |
| Normal | 2 (3.85%) | |
| RET | 1 (1.92%) | |
| SDHA | 1 (1.92%) | |
| SDHB | 14 (26.9%) | |
| SDHD | 5 (9.62%) | |
| Sporadic | 20 (38.5%) | |
| VHL | 5 (9.62%) | |
| Location | 50 | |
| EAPGL | 21 (42.0%) | |
| HNPGL | 7 (14.0%) | |
| PCC | 22 (44.0%) | |
| Metastatic | 50 | |
| No | 20 (40.0%) | |
| Unknown | 22 (44.0%) | |
| Yes | 8 (16.0%) | |
| Primary | 50 | |
| No | 4 (8.00%) | |
| Unknown | 22 (44.0%) | |
| Yes | 24 (48.0%) | |
| Recurring | 50 | |
| No | 21 (42.0%) | |
| Unknown | 22 (44.0%) | |
| Yes | 7 (14.0%) | |
| Clinically aggressive | 50 | |
| No | 17 (34.0%) | |
| Unknown | 22 (44.0%) | |
| Yes | 11 (22.0%) | |
| ATRX double mutation: | 50 | |
| No | 24 (48.0%) | |
| Unknown | 22 (44.0%) | |
| Yes | 4 (8.00%) | |
| Cluster | 52 | |
| Cluster 1A | 21 (40.4%) | |
| Cluster 1B | 5 (9.62%) | |
| Cluster 2 | 4 (7.69%) | |
| Normal | 2 (3.85%) | |
| Sporadic | 20 (38.5%) | |
| Sex | 52 | |
| F | 15 (28.8%) | |
| M | 21 (40.4%) | |
| Unknown | 16 (30.8%) | |
| Tissue | 52 | |
| Normal adrenal medulla | 2 (3.85%) | |
| Tumour | 50 (96.2%) |
The location of the tumour site is listed (location) since this is relevant to DNA methylation pattern. The behaviour of the tumour is described as aggressive or metastatic or neither. EAPGL: Extra-adrenal paraganglioma (i.e. of the thorax, abdomen or pelvis). HNPGL: Head and neck paraganglioma. PCC: Phaeochromocytoma